Menigiomas are formed by the intracranial arachnoid membrane. Meningiomas account for 15%-25% of intracranial tumors, second only to gliomas, and are the most common benign intracranial tumors. Because of their slow growth and mild or no clinical symptoms, their treatment rate is lower than that of pituitary adenomas among benign intracranial tumors. Meningiomas can occur in any part of the skull, more often in the supratentorial than in the infratentorial area, with the following order of prevalence: cerebral convexity, sagittal sinus, pars falciformis and skull base. Meningiomas in the convex and pars falciform areas of the brain show early and obvious clinical symptoms and have a high chance of causing neurological deficits and increased intracranial pressure, and should be treated early. Meningiomas are usually rich in vascular components and have a good blood supply, usually from the dura mater (external carotid artery system) and partly from the cortical arteries (internal carotid or vertebral artery). Meningiomas can invade the venous sinuses, skull, temporalis muscle and scalp. For this reason, the scope of surgery is often enlarged and the complexity and difficulty of surgery is increased. Therefore, the recurrence rate is high despite surgery in this state. Auxiliary diagnosis In addition to clinical manifestations, cranial CT and MRI examination are irreplaceable bases for diagnosis and treatment. MRI has three-dimensional imaging and multi-imaging series, which are not affected by bone artifacts and are especially good for showing tumors in the skull base, posterior cranial fossa and orbit, facilitating the design of treatment plans and protecting sensitive structures in the skull. Meningiomas generally have diagnostic features such as round/ or semicircular shape, clear borders, wide base, caudal sign, occupancy effect and uniform enhancement. Surgery is the preferred method for meningioma, with a recurrence rate of 9% to 40% after surgical resection. At the same time, some patients who are unable to undergo surgery due to organic diseases of the system or those who have residual surgery must seek more suitable treatment methods. Gamma Knife is the first treatment for meningioma that is suitable for surgical residuals or surgical recurrence, for meningioma ≤ 30 mm in diameter in any area, or for meningioma patients who are not suitable for surgery. Gamma knife treatment for meningioma can achieve the purpose of controlling tumor growth, preventing neurological dysfunction and neurological irritation (epilepsy) due to tumor growth. Patients with meningioma who have significant functional deficits due to tumor dominance should be considered for surgery immediately and should not be treated with Gamma Knife. On the contrary, those without occupancy effect and tumor diameter ≤ 30 mm can be preferred to gamma knife treatment. After 15-30 years of clinical practice has confirmed that the prescription dose of gamma knife for meningioma treatment is safe and reliable, which undoubtedly expands the space for its treatment, ensures the safety of treatment and reduces the chance of co-morbidity. Gamma Knife is particularly suitable for meningiomas in the orbit, intraventricular sinus, intracerebroventricular, paracavernous-cavernous sinus, saddle, slope and other hidden areas. Meningiomas at the base of the skull or deep in the skull of elderly and frail patients can be treated safely and effectively even if they are larger than 30 mm in diameter. Gamma knife is an effective method to prevent recurrence of meningioma by irradiating the basal part of the tumor (tumor bed) after surgery for large size or anatomically complex meningioma.